Department of Biology, College of Science, Taibah University, Madinah, Kingdom of Saudi.
Department of Oncology, King Fahad Hospital, Madinah, Kingdom of Saudi Arabia.
Asian Pac J Cancer Prev. 2020 Nov 1;21(11):3235-3240. doi: 10.31557/APJCP.2020.21.11.3235.
The present study aimed to determine the role of ESR1 gene rs2234693 T/C polymorphism (PvuII) in the susceptibility to breast cancer and to assess the association of this polymorphism within presence or absence of estrogen, progesterone receptors, human epidermal growth factor receptor 2 (HER2) and with premenopausal and postmenopausal age in Saudi women.
The study was a retrospective case-control study. In this study, 137 breast cancer and 98 normal breast paraffin embedded tissues were included. DNA was extracted and ESR1 gene rs2234693 T/C polymorphism was genotyped by PCR-RFLP. Genetic association tests were performed.
The results showed no significant difference in distribution of rs2234693 T/C alleles and genotypes frequencies. Odd ratios (95% CI) were 1.15 (0.8-1.66) and 1.06 (0.5-1.98) and p values were 0.51 and 0.87, respectively. The genotypes and alleles frequencies within different hormonal receptors groups and ages of menopause showed no signification association (odd ratios were less or close to 1 and p values > 0.05).
ESR1 gene rs2234693 T/C polymorphism was not associated with susceptibility to breast cancer and different menopausal, hormone receptors, and HER2 status in breast cancer patients. Further analysis using larger sample size will be needed to assess the association of different polymorphisms within the gene and risk of breast cancer.
本研究旨在确定 ESR1 基因 rs2234693 T/C 多态性(PvuII)在乳腺癌易感性中的作用,并评估该多态性与雌激素、孕激素受体、人表皮生长因子受体 2(HER2)的存在或缺失以及在沙特女性中的绝经前和绝经后年龄的相关性。
本研究为回顾性病例对照研究。本研究纳入了 137 例乳腺癌和 98 例正常乳腺石蜡包埋组织。提取 DNA,采用 PCR-RFLP 法对 ESR1 基因 rs2234693 T/C 多态性进行基因分型。进行遗传关联检验。
结果显示,rs2234693 T/C 等位基因和基因型频率的分布无显著差异。比值比(95%CI)分别为 1.15(0.8-1.66)和 1.06(0.5-1.98),p 值分别为 0.51 和 0.87。不同激素受体组和绝经年龄的基因型和等位基因频率无显著相关性(比值比小于或接近 1,p 值>0.05)。
ESR1 基因 rs2234693 T/C 多态性与乳腺癌易感性以及乳腺癌患者不同的绝经状态、激素受体和 HER2 状态无关。需要进一步使用更大的样本量进行分析,以评估该基因内不同多态性与乳腺癌风险的相关性。